UNI DEGLI STUDI DI VERONA has a total of 16 patent applications. Its first patent ever was published in 2002. It filed its patents most often in WIPO (World Intellectual Property Organization), Italy and Australia. Its main competitors in its focus markets biotechnology, pharmaceuticals and measurement are ATTOGEN BIOMEDICAL SUZHOU INC LTD, HILDEBRAND WILLIAM H and ST LUKE S ROOSEVELT HOSPITAL C.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 7 | |
#2 | Italy | 4 | |
#3 | Australia | 2 | |
#4 | EPO (European Patent Office) | 2 | |
#5 | United States | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals | |
#3 | Measurement | |
#4 | Environmental technology |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Analysing materials | |
#3 | Peptides | |
#4 | Microorganisms | |
#5 | Climate change adaptation technologies | |
#6 | Measuring microorganism processes | |
#7 | Microbiology |
# | Name | Total Patents |
---|---|---|
#1 | Lunardi Claudio | 5 |
#2 | Puccetti Antonio | 5 |
#3 | Suzuki Hisanori | 3 |
#4 | Zanoni Giovanna | 3 |
#5 | Avesani Linda | 3 |
#6 | Falorni Alberto | 3 |
#7 | Cavalieri Elisabetta | 3 |
#8 | Pezzotti Mario | 3 |
#9 | Frulloni Luca | 2 |
#10 | Giovinazzo Francesco | 1 |
Publication | Filing date | Title |
---|---|---|
WO2013053901A1 | METHOD FOR DETECTION OF Gα15 AS TUMOR MARKER IN PANCREATIC CANCER | |
WO2011104612A2 | Device for cell culture and analysis | |
EP2488865A1 | Antibody associated with autoimmune pancreatitis and uses thereof | |
EP2318534A1 | Method for the expression in plant of the glutamic acid decarboxylase (gad65) and related expression vectors the present invention concerns a method of expression in plant of glutamic acid decarboxylase (gad65), particularly a mutated form of human gad65 (gad65mut), and expression vectors thereof. | |
WO2008122294A1 | Peptides, antibodies and fragments thereof for the treatment and diagnostic of celiac disease | |
AU2003233186A1 | Pharmaceutical compositions with anti-tumour activity, in particular for the treatment of leukaemia and glioblastomas |